Key SummaryBLA Filing Milestone:Dyne Therapeutics, Inc. (Nasdaq: DYN) has filed a Biologics License Application (BLA) for its dystrophin-based therapy, marking a significant regulatory milestone towards commercialization in the dystrophic muscular dystrophy (DMD) market.Enrolled Trial Participants:Enrollment has been completed for the company's DM1 trial, supporting …
Eli Lilly & Company (NYSE: LLY), the world's largest pharmaceutical company, has announced that it will use the financial windfall from its GLP-1 medications, such as Mounjaro and Zepbound, to fund its aggressive dealmaking strategy. This shift in approach marks a significant departure from …
Dollar General Corp (NYSE: DG) has been maintained at an in-line rating by Evercore ISI Group. This decision suggests the analyst group remains neutral on the retail company's performance.
Copa Holdings, theParent Companyof Copa Airlines, has received an Overweight rating from JP Morgan, a majorWall StreetInvestmentbank. This assessment reflects the bank's expectations for the company's future prospects.
Key SummaryPrivatePayrollGrowth:ADP reports 122,000 new jobs in May, exceeding the expected 110,000, with the strongest month since January 2025.Sectoral Distribution:The gains were more broad-based, with eight of the 10 sectors tracked by ADP showing increases, while two sectors reported losses.Salary Growth:Annual pay rose 4.4% …
Invesco High Income Trust II announced portfolio management changes, naming Thomas Moore and Rahim Shad as the joint and primary responsible individuals for the day-to-day management of the fund's portfolio. These changes took effect on June 3, 2026.
Fulcrum Therapeutics Inc. (Nasdaq: FULC) lost approximately 50% of its value in a single session after disclosing that the FDA had raised class-wide safety concerns about PRC2-targeting agents. This dramatic price drop was triggered by the Company's decision to discontinue its lead candidate pociredir, …
Lululemon Athletica Inc. (NASDAQ: LULU) has been rated as in-line by the Evercore ISI Group.